scholarly journals Acroangiodermatitis or pseudo-Kaposi’s sarcoma: a challenging diagnosis

2021 ◽  
Vol 12 (e) ◽  
pp. e72-e72
Author(s):  
Hanan Ragragui; Ouasmin ◽  
Soraya Aouali ◽  
Nada Zizi ◽  
Siham Dikhaye
Keyword(s):  
Blood Vessels ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Immunohistochemical Analysis ◽  
Lower Limbs ◽  
Vascular Lesions ◽  
Cutaneous Lesions ◽  
Clinical Variants ◽  
Proliferative Disease ◽  
Reactive Proliferation

Acroangiodermatitis (AAD), also referred to as pseudo-Kaposi’s sarcoma, is a vascular-proliferative disease characterized by reactive proliferation of small blood vessels in response to congenital or acquired vascular lesions. There are mainly two clinical variants of acroangiodermatitis; STEWART-BLUEFARB syndrome and the Malian type. There is clinical and histological similarity with Kaposi’s sarcoma hence the interest of immunohistochemical analysis. We report the case of a 40-year-old man with cutaneous lesions localized on the lower limbs. Clinical, dermoscopic, histological and immunohistochemical investigation led to a diagnosis of Kaposi-like acroangiodermatitis.

scholarly journals Cutaneous Horn-Related Kaposi's Sarcoma: A Case Report

2010 ◽  
Vol 2010 ◽  
pp. 1-3 ◽  
Author(s):  
Nilufer Onak Kandemir ◽  
Banu Dogan Gun ◽  
Figen Barut ◽  
Nilgun Solak Tekin ◽  
Sukru Oguz Ozdamar
Keyword(s):  
Case Report ◽  
Kaposi's Sarcoma ◽  
Histopathological Examination ◽  
English Literature ◽  
Kaposi’S Sarcoma ◽  
Immunohistochemical Analysis ◽  
Cutaneous Lesions ◽  
Cutaneous Horn ◽  
Neoplastic Lesion ◽  
Macroscopic Examination

Cutaneous horn is characterized by the accumulation of abnormal keratinized material and may occur in association with a variety of benign, premalignant, and malignant cutaneous lesions. Cutaneous horn occurs very rarely in association with soft-tissue neoplasias. A cutaneous horn located on the toe was completely removed by excision in a 78-year-old male patient. Macroscopic examination revealed a hemorrhagic nodular lesion, 0.5 cm in diameter, located on the dermis underlying the cutaneous horn with a height of 1 cm. Histopathological examination revealed a neoplastic lesion consisting of fusiform cells and extravasated erythrocytes underlying the compact keratin mass. The immunohistochemical analysis showed immunoexpression of endothelial markers and HHV8 in fusiform cells. The case was evaluated as “cutaneous horn developed in a nodular stage Kaposi's sarcoma.” Our case is the second case of cutaneous horn related to Kaposi's sarcoma reported in the English literature and is presented in this case report with its clinical and histopathological features.

scholarly journals Transplant-associated penile Kaposi sarcoma managed with single agent paclitaxel chemotherapy: a case report

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Matthew A. Anderson ◽  
Tracey Ying ◽  
Kate Wyburn ◽  
Peter M. Ferguson ◽  
Madeleine C. Strach ◽  
...  
Keyword(s):  
Kaposi's Sarcoma ◽  
Single Agent ◽  
Lower Extremities ◽  
Kaposi’S Sarcoma ◽  
The Body ◽  
Cutaneous Lesions ◽  
Rare Presentation ◽  
Post Transplant ◽  
Transplant Patients ◽  
Disseminated Disease

Abstract Background Kaposi’s sarcoma is an uncommon complication in renal transplant patients, and typically presents with cutaneous lesions on the lower extremities. Penile involvement has been reported only rarely. Management of cutaneous-limited disease is primarily reduction of immunosuppression and conversion to an mTOR-inhibitor, whereas the treatment of disseminated disease in transplant patients is more variable. Case presentation A 75-year-old male, originally from Somalia, received a deceased-donor kidney transplant for diabetic and hypertensive nephropathy. Seven months post-transplant he presented with lower limb lesions, oedema and bilateral deep vein thromboses. He then developed a fast-growing painful lesion on his penile shaft. A biopsy of this lesion confirmed KS, and a PET scan demonstrated disseminated disease in the lower extremities, penis and thoracic lymph nodes. His tacrolimus was converted to sirolimus, and his other immunosuppression was reduced. He was treated with single agent paclitaxel chemotherapy in view of his rapidly progressing, widespread disease. The penile lesion completely resolved, and the lower extremity lesions regressed significantly. His kidney allograft function remained stable throughout treatment. Conclusion This case illustrates a rare presentation of an uncommon post-transplant complication and highlights the need for a high index of suspicion of KS in transplant patients presenting with atypical cutaneous lesions. It serves to demonstrate that the use of single agent paclitaxel chemotherapy, switch to an mTORi and reduction in immunosuppression where possible produces excellent short-term outcomes, adding to the body of evidence for this management strategy in disseminated Kaposi’s sarcoma.

Kaposi Sarcoma of the Lower Extremity with HIV and Kaposi's Sarcoma

2021 ◽  
Vol 2 (1) ◽  
pp. 01-03
Author(s):  
Selma Bakar Dertlioğlu
Keyword(s):  
Antiretroviral Therapy ◽  
Oral Cavity ◽  
Lower Extremity ◽  
Respiratory System ◽  
Kaposi's Sarcoma ◽  
Kaposi Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Newly Diagnosed ◽  
Clinical Variants ◽  
Common Malignancy

Kaposi's sarcoma is the most common malignancy seen with HIV infection. It is a lymphoangioproliferous tumor first described by Moritz Kaposi in 1872. It is characterized by bluish red or dark brown plaques and nodules, especially in the distal of the lower extremities, often the heels and feet. Organ involvement without skin findings is observed in approximately 15% of the cases. There are four clinical variants, the classical, endemic, iatrogenic and the epidemic associated with AIDS. Kaposi's sarcoma in AIDS cases apart from the skin, it can also be seen in the oral cavity, gastro-intestinal system and respiratory system. Antiretroviral therapy (ART) should be started immediately in newly diagnosed HIV infected patients. In this research, a 65 year old male patient, who was diagnosed AIDS and Kaposi's sarcoma at the same time, is described.

scholarly journals Rapid Progression of Kaposi’s sarcoma complicated with hemophagocytic syndrome in a severely immunosuppressed patient with HIV-infection: a case report

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Pingzheng Mo ◽  
Liping Deng ◽  
Xiaoping Chen ◽  
Yong Xiong ◽  
Yongxi Zhang
Keyword(s):  
Hiv Infection ◽  
Kaposi's Sarcoma ◽  
Hemophagocytic Syndrome ◽  
Kaposi’S Sarcoma ◽  
Rapid Progression ◽  
Immunosuppressed Patient ◽  
Timely Manner ◽  
Cutaneous Lesions ◽  
Case Presentation ◽  
Life Threatening

Abstract Background AIDS-related KS generally involves cutaneous lesions, that slowly progress over months to years. Neither rapidly progressing of KS nor KS complicated with hemophagocytic syndrome (HPS) has rarely been reported. Case presentation We report a rare case of rapid progression of Kaposi’s sarcoma complicated with hemophagocytic syndrome in a severely immunosuppressed patient with HIV-infection. The symptoms of this patient were atypical, showing only persistent high fever and rapid progressed to hemophagocytic syndrome. This patient was successfully treated with antiretroviral therapy combined with liposomal doxorubicin. Conclusions The condition of the KS patient could deteriorate rapidly over a period of days and even developeded into HPS, which was life-threatening. However, chemotherapy initiated in a timely manner might improve prognosis.

Immunohistochemical analysis of procathepsin L and cathepsin B in cutaneous Kaposi's sarcoma

1997 ◽  
Vol 36 (2) ◽  
pp. 100-103 ◽  
Author(s):  
Matthias Thewes ◽  
Reinhard Engst ◽  
Maren Jurgens ◽  
Siegfried Borelli
Keyword(s):  
Cathepsin B ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Immunohistochemical Analysis ◽  
Procathepsin L

scholarly journals Dermatomyositis with Kaposi’s Sarcoma in a Patient without Human Immunodeficiency Virus-1 Infection

1991 ◽  
Vol 5 (1) ◽  
pp. 1-4
Author(s):  
Dana Liang ◽  
Andrew Szilagyi ◽  
Robin C Billick ◽  
Herbert Srolovitz ◽  
Ricardo Bullen
Keyword(s):  
Human Immunodeficiency Virus ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Definitive Diagnosis ◽  
Gastrointestinal Involvement ◽  
Cutaneous Lesions ◽  
First Case ◽  
Immunodeficiency Virus ◽  
Human Immunodeficiency Virus 1

The first case of dermatomyositis complicating cutaneous and visceral Kaposi’s sarcoma is presented in a 75-year-old man without human immunodeficiency virus infection. Dermatomyositis preceded a definitive diagnosis of Kaposi’s sarcoma by six months, although in retrospect unrecognized lesions may have presented simultaneously. He was treated with prednisone and azathioprine, thus raising the possibility of the role of immunosuppression in promoting progression of the sarcoma. It is suggested that although the association between dermatomyositis and Kaposi’s sarcoma occurs rarely, dermatomyositis should be considered a paraneoplastic syndrome of Kaposi’s sarcoma. Further, the finding of cutaneous lesions of Kaposi’s sarcoma could predict gastrointestinal involvement when dermatomyositis and Kaposi’s sarcoma occur in the same patient.

Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.

1998 ◽  
Vol 16 (4) ◽  
pp. 1444-1449 ◽  
Author(s):  
B J Dezube ◽  
J H Von Roenn ◽  
J Holden-Wiltse ◽  
T W Cheung ◽  
S C Remick ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Partial Response ◽  
Kaposi's Sarcoma ◽  
Single Agent ◽  
Angiogenesis Inhibitor ◽  
Kaposi’S Sarcoma ◽  
Trial Group ◽  
Cutaneous Lesions ◽  
Aids Clinical Trial Group ◽  
Dose Levels

PURPOSE Angiogenesis is a major component of Kaposi's sarcoma (KS) and a critical process in tumor growth. The present study was designed primarily to test the toxicity and pharmacokinetics (PK) of the angiogenesis inhibitor TNP-470 and secondarily to evaluate tumor response in patients with early AIDS-related KS. PATIENTS AND METHODS Patients with AIDS-related KS were required to have cutaneous disease with > or = 5 measurable lesions and no evidence of pulmonary, symptomatic gastrointestinal, or acutely life-threatening KS. Thirty-eight patients received TNP-470 by weekly intravenous infusion over 1 hour at one of six dose levels for up to 24 weeks. RESULTS The dose levels tested included 10, 20, 30, 40, 50 and 70 mg/m2. Median CD4 count was 24 cells/microl (range, 0 to 460). Fourteen patients (36%) had > or = 50 cutaneous lesions and 19 (49%) had oral lesions. Adverse events included neutropenia (n = 2), hemorrhage (n = 3), and urticaria (n = 1). PK studies showed wide interpatient and intrapatient variability. Elimination half-life values were short (range, 0.01 to 0.61 hours). Seven patients (18%) achieved a partial response. The median time to partial response was 4 weeks (range, 2 to 25), and the median duration of response was 11 weeks (range, 3 to 26+). CONCLUSION TNP-470, administered as a weekly, 1-hour infusion to patients with early AIDS-KS is well-tolerated at doses up to and including the highest dose tested. Tumor responses were observed in a substantial number of cases and occurred at various dose levels. TNP-470 should be evaluated further in patients with AIDS-KS as a single agent and in combination with other biologic response modifiers in early disease or after initial response to cytotoxic chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document